Long-term outcome of a DLI-based treatment strategy in patients with relapsed AML after TCD allogeneic stem cell transplantation is hampered by GvHD and late relapse.
BACKGROUND Relapse of acute myeloid leukemia (AML) after allogeneic stem cell transplantation (alloSCT) remains a major cause of treatment failure, with poor long-term survival. Donor lymphocyte infusion (DLI) can induce a graft-versus-leukemia effect but may also lead to graft-versus-host disease (GvHD) associated mor...